Concepedia

Gregory T. Golm

GT

Statistics

Publications

40

Citations

2.9K

H-Index

30

Active since

1993

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Pfizer (United States)

Inserm

University of California San Diego

University of Colorado Anschutz Medical Campus

Gregory T. Golm is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in diabetes mellitus, pharmacotherapy, and diabetes management.

Publications per year

1993–2025

40

Publications

40

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

Debora Williams‐Herman, Samuel S. Engel, Elizabeth Round et al. · BMC Endocrine Disorders · 2010 · 255 citations · Full text

, , +14

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)

Christopher P. Cannon, Darren K. McGuire, Richard E. Pratley et al. · American Heart Journal · 2018 · 205 citations · Full text

, , +17

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The <scp>VERTIS FACTORIAL</scp> randomized trial

Richard E. Pratley, Roy Eldor, Annaswamy Raji et al. · Diabetes Obesity and Metabolism · 2017 · 164 citations · Full text

, , +16

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The <scp>VERTIS SITA2</scp> placebo‐controlled randomized study

Samuel Dagogo‐Jack, Jie Liu, Roy Eldor et al. · Diabetes Obesity and Metabolism · 2017 · 160 citations · Full text

, , +11

Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency

Juan Camilo Arjona Ferreira, Michel Marre, Nir Barzilai et al. · Diabetes Care · 2012 · 159 citations · Full text

, , +14

1–5 of 40